What is Psoriatic Arthritis?
Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis that manifests with peripheral arthritis, dactylitis, enthesitis, and spondylitis, affecting men and women equally and requiring early recognition to prevent irreversible joint damage and disability. 1
Core Disease Characteristics
PsA is an immune-mediated inflammatory condition that attacks multiple anatomical sites simultaneously. The disease targets:
- Peripheral joints: Can present as asymmetric oligoarthritis (≤4 joints) or symmetric polyarthritis (≥5 joints), with distal interphalangeal joints commonly affected 1
- Entheses: Inflammation where tendons and ligaments insert into bone, particularly at plantar fascia, Achilles tendons, and ligamentous attachments to ribs, spine, and pelvis 2
- Dactylitis: "Sausage digit" appearance from combined enthesitis and synovitis affecting entire fingers or toes 2
- Axial skeleton: Spondylitis usually occurs with peripheral arthritis 1
- Nails: Pitting and onycholysis occur in 80-90% of patients with PsA 1
Epidemiology and Timeline
The prevalence is 1-2 per 1,000 in the general population, with an incidence of 6 per 100,000 per year 1. Among patients with psoriasis, 6-41% will develop PsA, with higher rates (30-33%) in clinic-based populations 2, 3.
Critical timing pattern: In 72-84% of patients, skin disease precedes arthritis by an average of 10-12 years 2, 3. However, in 10-15% of cases, arthritis appears first, and in some patients both manifest simultaneously 1, 3. This makes dermatologists uniquely positioned for early detection 2.
Peak onset occurs between ages 30-50 years, affecting both sexes equally 2, 4.
Clinical Presentation and Warning Signs
Key symptoms to actively screen for at every visit 2:
- Early morning stiffness lasting >30 minutes
- Joint pain, swelling, and tenderness
- Whole digit swelling (dactylitis)
- Heel or foot pain (enthesitis)
- Nail changes (pitting, onycholysis, especially with DIP joint involvement)
The severity of skin and joint disease do not correlate 2. Patients can have severe arthritis with minimal skin involvement, or extensive psoriasis without joint disease.
Disease Course and Prognosis
Without treatment, PsA follows a destructive path: 40-60% of patients in rheumatology centers develop erosive and deforming arthritis, potentially within the first year of diagnosis 2, 4. The disease causes:
- Progressive joint damage and structural destruction
- Severe physical limitations and disability
- Reduced quality of life 1
- Increased mortality associated with greater disease activity 1
The course is characterized by unpredictable flares and remissions 2. Some patients develop rapidly progressive arthritis mutilans—a severely destructive form 1.
Associated Comorbidities
PsA is a systemic disease with increased risk for 3:
- Cardiovascular disease (both clinical and subclinical)
- Metabolic syndrome and diabetes
- Inflammatory bowel disease
- Mental health disorders (anxiety/depression)
- Obesity
Why Early Recognition Matters
Early identification and treatment initiation are critical for improving long-term outcomes 1. The window before irreversible joint damage occurs is limited, making proactive screening essential at every patient encounter with psoriasis 3. Dermatologists must maintain high clinical suspicion, as they often see patients years before arthritis symptoms become obvious 2, 4.
Pathophysiology
PsA involves T-cell infiltration with increased vascularity in synovial tissue, neutrophil infiltration, and potential roles for IL-12/23 pathways 4. The disease demonstrates the paradoxical combination of bone erosion alongside new bone formation, distinguishing it from other inflammatory arthritides 5.